Summit Therapeutics out-licenses ridinilazole for Latin America

British biotech Summit Therapeutic (AIM: SUMM) has entered into a licensing agreement with Brazil-based Eurofarma Laboratórios granting rights in Latin America to Summit's precision antibiotic ridinilazole in development for the treatment of Clostridium difficile infection (CDI). Summit retains commercialization rights in all other countries.

Ridinilazole is a targeted antibiotic that has the potential as a frontline therapy to treat initial infection and preserve patients' microbiomes to reduce the rate of recurrent CDI. In a Phase II proof of concept trial in CDI patients, ridinilazole demonstrated statistical superiority in sustained clinical response (SCR) rates compared to the standard of care, vancomycin. Ridinilazole is expected to enter Phase III clinical trials in the first half of 2018.

Financial terms of the deal